Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03211247
Registration number
NCT03211247
Ethics application status
Date submitted
5/07/2017
Date registered
7/07/2017
Titles & IDs
Public title
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
Query!
Scientific title
A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.
Query!
Secondary ID [1]
0
0
EPITOPE
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EPITOPE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Peanut Allergy
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Allergies
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Viaskin Peanut 250 mcg
Treatment: Other - Viaskin Peanut 100 mcg
Treatment: Other - Placebo
Experimental: Viaskin Peanut 250 mcg -
Experimental: Viaskin Peanut 100 mcg -
Placebo comparator: Placebo -
Treatment: Other: Viaskin Peanut 250 mcg
Viaskin Peanut 250 mcg, once daily
Treatment: Other: Viaskin Peanut 100 mcg
Viaskin Peanut 100 mcg, once daily
Treatment: Other: Placebo
Placebo patch, once daily
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Differences between the percentage of treatment responders in the selected active Viaskin Peanut group compared to the placebo group.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Month 12
Query!
Eligibility
Key inclusion criteria
Key
* Male or female from 1-3 years of age;
* Physician-diagnosed peanut allergy;
* Peanut-specific IgE level > 0.7 kU/L;
* Positive peanut SPT with a largest wheal diameter = 6 mm;
* Positive DBPCFC at = 300 mg peanut protein;
Key
Query!
Minimum age
1
Year
Query!
Query!
Maximum age
3
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Uncontrolled asthma;
* History of severe anaphylaxis to peanut;
* Prior immunotherapy to any food or other immunotherapy;
* Generalized severe dermatologic disease;
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/07/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/04/2022
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
414
Query!
Recruitment in Australia
Recruitment state(s)
NSW,NWSQLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
The Children's Hospital at Westmead - Westmead
Query!
Recruitment hospital [2]
0
0
Sydney Children's Hospital - Randwick
Query!
Recruitment hospital [3]
0
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment hospital [4]
0
0
The Women's and children's hospital - North Adelaide
Query!
Recruitment hospital [5]
0
0
The Royal Children's Hospital - Parkville
Query!
Recruitment hospital [6]
0
0
Perth Children's Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5006 - North Adelaide
Query!
Recruitment postcode(s) [5]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [6]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
District of Columbia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
British Columbia
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Lille
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Metz
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Nice
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Vandoeuvre les nancy
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Dresden
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Frankfurt
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Marburg
Query!
Country [30]
0
0
Ireland
Query!
State/province [30]
0
0
Cork
Query!
Country [31]
0
0
Netherlands
Query!
State/province [31]
0
0
Rotterdam
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
London
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Manchester
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
Sheffield
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
DBV Technologies
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
Query!
Trial website
https://clinicaltrials.gov/study/NCT03211247
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03211247